Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 21, Issue 5 SUPPL. 31, 2003, Pages

  Mullan, Ronan H ^a   Bresnihan, Barry ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Antirheumatic agents; Disease progression; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; DICLOFENAC; DIHYDROFOLATE REDUCTASE INHIBITOR; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE;

CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; INHIBITION KINETICS; MITOSIS INHIBITION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRELAND; MALE; METHOTREXATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0142029665     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-40.
2. BUKHARI M, HARRISON B, LUNT M, SCOTT DG, SYMMONS DP, SILMAN AJ: Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum 2001; 44: 1248-53.
3. FUCHS HA, KAYE JJ, CALLAHAN LF, NANCE EP, PINCUS T: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585-91.
4. van LEEUWEN MA, van RIJSWIJK, van der HEIJDE DM, et al.: The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32(Suppl. 3): 9-13.
5. van der HEIJDE DM, van LEEUWEN MA, van RIEL PL, van de PUTTE LB: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792-6.
6. WOLFE F, SHARP JT: Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 1571-82.
7. DROSSAERS-BAKKER KW, DE BUCK M, VAN ZEBEN D, ZWINDERMAN AH, BREEDVELD FC, HAZES JM: Long term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-60.
8. McGONAGLE D, CONAGHAN PG, O'CONNOR P, et al.: The relationship between synovitis and bone changes in early untreated rheumatoid arthritis. Arthritis Rheum 1999; 42: 1706-11.
9. BRESNIHAN B: Rheumatoid arthritis: principles of early treatment. J Rheumatol 2002; 66 (Suppl.) : 9-12.
10. DORAN MF, POND GR., CROWSON CS, O'FALLON WM, GABRIEL SE: Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625-31.
11. MUTRU O, LAAKSO M, HEIKKI I, KOOTA K: Cardiovascular mortality in Patients with Rheumatoid Arthritis. Cardiology 1989; 76: 71-7.
12. GUILLEMIN F: Functional disability and quality-of-lite assessment in clinical practice. Rheumatology (Oxford) 2000; 39 (suppl. 1): 17-23.
13. RIISE T, JACOBSEN BK, GRAN JT, HAGA HJ, ARNESEN E: Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 2001; 30: 123-7.
14. WOLFE F, MITCHELL DM, SIBLEY JT, et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
15. COOPER NJ: Economic burden of rheumatoid arthritis: A systematic review. Rheumatology (Oxford) 2000; 39: 28-33.
16. DEVLIN J, GOUGH A, HUISSOON A, et al.: The acute phase and function in early RA. CRP levels correlate with functional outcome. J Rheumatol 1997; 24: 9-13.
17. GUILLEMIN F, SUURMEIJER T, KROL B, et al.: Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 1994; 21: 1051-5.
18. SITUNAYAKE RD, McCONKEY B: Clinical and laboratory effects of prolonged therapy with sulphasalazine, gold or penicillamine: the effects of disease duration on treatment response. J Rheumatol 1990; 17: 1268-73.
19. BOERS M, VERHOEVEN AC, MARKUSSE HM, et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
20. EGSMOSE C, LUND B, BORG G, et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
21. STENGER AA, VAN LEEUWEN MA, HOUTMAN PM, et al.: Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37: 1157-63.
22. van JAARSVELD CH, JACOBS JW, van der VEEN MJ, et al.: Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis 2000; 59: 468-77.
23. MÖTTÖNEN T, HANNONEN P, MARKKU K, et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
24. MUNRO R, HAMPSON R, MCENTEGART A, THOMSON EA, MADHOK R, CAPELL H: Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998; 57: 88-93.
25. PINCUS T, CALLAHAN LF: What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 123-51.
26. HARRISON BJ, SYMMONS DP, BRENNAN P, BARRETT BE, SILMAN AJ: Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996; 35: 1096-100.
27. PINCUS T, CALLAHAN LF: Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favourable outcomes than studies of patients with established disease. Br J Rheumatol 1995; 34: 196-9.
28. PULLAR T, HUNTER JA, CAPELL JA: Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987; 46: 398-402.
29. van der HEIJDE DM, van RIEL PL, NUVERZWART IH, GRIBNAU FW, van de PUTTE LB: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8.
30. WEINBLATT ME, COBLYN JS, FOX DA, et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
31. WILLIAMS HJ, WILLKENS RF, SAMUELSON CO, et al.: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28: 721-30.
32. DROSOS AA, TSIFETAKE N, TSIAKOU EK, et al.: Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol 1997; 15: 263-7.
33. RODNAN GP, BENEDEK TG: The early history of anti-rheumatic drugs. Arthritis Rheum 1970; 13: 146-65.
34. SIGLER JW, BLUHM GB, DUNCAN H, SHARP JT, ENSIGN DC, McCRUM WR: Gold salts in the treatment of rheumatoid arthritis. A double blind study. Ann Int Med 1974: 80: 21-6.
35. SHARP JT, LIDSKY MD, DUFFY J: Clinical responses during gold therapy for rheumatoid arthritis. Changes in synovitis, radiologically detectable erosive lesions, serum proteins and serologic abnormalities. Arthritis Rheum 1982; 25: 540-9.
36. RAU R, HERBORN G, MENGER H, SANGHA O: Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular gold. Extension of a one-year double-blind study in 174 patients. Rheumatology(Oxford) 2002; 41: 196-204.
37. PELTOMAA R, PAIMELA L, HELVE T, LEIRISALO-REPO M: Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. Scand J Rheumatol 1995; 24: 330-5.
38. KVEIN TK, ZEIDLER HK, HANNONEN P, et al.: Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: A three year study of radiographic progression, renal function and arterial hypertension. Ann Rheum Dis 2002; 61: 511-6.
39. WALLACE DJ: Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 243-63.
40. LANDEWÉ RB, GOEI THÈ HS, van RIJTHOVEN AW, BREEDVELD FC, DIJKMANS BA: A randomized, double blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37: 637-43.
41. ACP J Club: A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 1995; 98: 156-68.
42. FURST DE, LINDSLEY H, BAETHGE B, et al.: Dose loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomised, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999; 42: 357-65.
43. SVARTZ N: Salazopyrin: a new sulfanilamide preparation. Acta Med Scand 1942; 110: 577-98.
44. COMER SS, JASIN HE: In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988; 31: 1111-6.
45. SYMMONS DP, SALMON M, FARR M, BACON PA: Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol 1988; 15: 575-579.
46. SHANAHAN F, NIEDERLEHNER A, CARRAMANZANA N, ANTON P: Sulfasalazine inhibits the binding to TNF alpha to its receptor. Immunopharmacology 1990; 20: 217-24.
47. CHOY EH, SCOTT DL, KINGSLEY GH, et al.: Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 2002; 20: 351-8.
48. HANNONEN P, MöTTöNEN T, HAKOLO M, OKA M: Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36: 1501-9.
49. KREMER JM, PHELPS CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-45.
50. GENESTIER L, PAILLOT R, FOURNEL S, FERRARO C, MIOSSEC P, REVILLARD JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998: 102: 322-8.
51. DOLHAIN RJ, TAK PP, DIJKMANS BA, DE KUIPER P, BREEDVELD FC, MILTENBURG AM: Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 502-8.
52. FIRESTEIN GS, PAINE MM, LITTMAN BH: Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of inraarticular corticosteroids. Arthritis Rheum 1991; 34: 1094-105.
53. RICH E, MORELAND LW, ALARCON GS: Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 1999; 26: 241-3.
54. MARAVIC M, BOLOGNA C, DAURES JP, JORGENSEN C, COMBE B, SANY J: Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol 1999; 26: 262-7.
55. GENOVESE MC, BATHON JM, MARTIN RW, et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
56. SHARP JT, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomised controlled trials of leflunamide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505.
57. COHEN S, CANNON GW, SCHIFF M, et al.: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
58. SCOTT DL, SMOLEN JS, KALDEN JR, et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 20: 913-23.
59. LIN CS, BOLTZ RC, SIEKIERKA JJ, SIGAL NH: FK-506 and cyclosporine A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 1991; 133: 269-84.
60. PASERO G, PRIOLO F, MARUBINI E, et al.: Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006-15.
61. ZEIDLER HK, KVIEN TK, HANNONEN P, et al.: Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998; 37: 874-82.
62. DROSOS AA, VOULGARI PV, KATSARAKI A, ZIKOU AK: Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol Int 2000; 19: 113-8.
63. HENCH PS, KENDALL EX, SLOCUMB CH, POLLEY HF: Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions: A study in clinical physiology. Arch Intern Med 1950; 85: 546-66.
64. YOUSSEF PP, TRIANTAFILLOU S, PARKER A, et al.: Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis: reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996; 39: 1970-9.
65. van EVERDINGEN AA, JACOBS JW, SIEWERTSZ van REESMA DR, BIJLSMA JW: Low-dose prednisolone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Int Med 2002; 136: 1-12.
66. KIRWAN JR: The efect of glucocorticoids on joint destruction in rheumatoid arthritis. N Eng J Med 1995; 333: 142-6.
67. HICKLING P, JACOBY RK, KIRWAN JR: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 1998; 37: 930-6.
68. PAULUS HE, DI PRIMEO D, SANDA M et al.: Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 2006; 27: 1632-7.
69. GIACOMELLI R, CIPRIANI P, MATUCCI CERINIC M, et al.: Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF alpha production without decreasing TNF alpha mRNA levels. An in vivo and in vitro study. Clin Exp Rheumatol 2002; 20: 365-72.
70. MARCHESONI A, BATTAFARANO N, ARREGHINI M, et al.: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 47: 59-66.
71. PROUDMAN SM, CONAGHAN PG, RICHARDSON B, et al.: Treatment of poor-prognosis early rheumatoid arthritis: A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Rheumatology (Oxford), 2000 43: 1809-19.
72. HAAGSMA CJ, VAN RIEL PL, DE JONG AJ, VAN DE PUTTE LB: Combination of sulphasalazine and dmethotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-8.
73. MÖTTÖNEN T, HANNONEN P, LEIRISALO-REPO M, et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FINRACo trial group. Lancet 1999; 353: 1568-73.
74. GERARDS AH, LANDEWÉ RB, PRINS AP, et al.: Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003; 62: 291-6.
75. LANDEWÉ RB, BOERS M., VERHOEVEN AC, et al.: COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief structural intervention. Arthritis Rheum 2002; 46: 346-56.
76. VOSKUYL AE, BOERS M: Can progression of radiographic joint damage be predicted early in rheumatoid arthritis? J Rheumatol 2003; 30: 905-7.
77. van LEEUWEN MA, van RIJSWIJK MH, SLUITER WJ, et al.: Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24: 20-7.
78. PAULUS HE, OH M, SHARP JT, et al.: Correlation of Single Time-Point Damage Scores with Observed Progression of Radiographic Damage During the First 6 Years of Rheumatoid Arthritis. J Rheumatol 2003; 30: 705-13.
79. MULHERIN D, FITGERALD O, BRESNIHAN B: Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996; 35: 1263-8.
80. SANY J, KALISKY S., COURET M, CUCHACOVICH M, DAURES JP: Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis. J Rheumatol 1990; 17: 1636-41.